Production (Stage)
China Pharma Holdings, Inc.
CPHI
$1.90
$0.0633.42%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -17.05% | -47.25% | -39.00% | -15.76% | -30.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.05% | -47.25% | -39.00% | -15.76% | -30.12% |
| Cost of Revenue | -23.35% | -41.91% | -20.47% | 55.91% | -6.87% |
| Gross Profit | 53.07% | -102.78% | -122.81% | -592.16% | -263.01% |
| SG&A Expenses | -0.27% | 8.05% | 9.99% | -25.92% | 7.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.10% | -30.12% | -13.17% | 49.05% | -3.05% |
| Operating Income | 17.19% | -0.97% | -52.11% | -204.95% | -130.47% |
| Income Before Tax | 17.82% | 0.63% | -43.76% | -142.51% | -100.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.82% | 0.63% | -43.76% | -142.51% | -100.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.82% | 0.63% | -43.76% | -142.51% | -100.82% |
| EBIT | 17.19% | -0.97% | -52.11% | -204.95% | -130.47% |
| EBITDA | -135.49% | -53.06% | -1,177.30% | -373.50% | -164.55% |
| EPS Basic | 66.42% | 68.65% | 78.04% | 74.58% | 75.66% |
| Normalized Basic EPS | 66.42% | 68.64% | 78.04% | 74.59% | 75.66% |
| EPS Diluted | 66.42% | 68.65% | 78.04% | 74.58% | 75.66% |
| Normalized Diluted EPS | 66.42% | 68.64% | 78.04% | 74.59% | 75.66% |
| Average Basic Shares Outstanding | 144.69% | 216.92% | 554.82% | 854.08% | 724.94% |
| Average Diluted Shares Outstanding | 144.69% | 216.92% | 554.82% | 854.08% | 724.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |